Blood pressure is not static. It fluctuates with every moment.
In the rural communities of South Korea, roughly 770 older adults will soon wear a small ring on their fingers that quietly records the rhythm of their blood pressure through each waking hour and sleeping night. The Korea National Institute of Health has enlisted Sky Labs' CART BP Pro — a cuffless wearable already woven into the country's reimbursement system — to anchor a large epidemiological study under the long-running KoGES program. The effort reflects a quiet but consequential shift in medicine: the recognition that a single reading taken in a clinic may tell us far less about a person's cardiovascular life than the continuous, unguarded data of ordinary existence. For aging populations in places far from urban hospitals, this kind of sustained, real-world observation may ultimately rewrite how hypertension is understood and treated.
- Blood pressure is not a fixed number — it rises and falls with stress, sleep, and movement — yet most clinical decisions still rest on a handful of snapshots taken in a doctor's office.
- Older adults in rural Korea face elevated cardiovascular risk while having the least access to consistent monitoring, creating a gap that conventional medicine has struggled to close.
- Sky Labs' ring device, already reimbursed for 24-hour ambulatory monitoring and endorsed in Korea's 2026 hypertension guidelines, is now being deployed at scale to capture continuous readings across hundreds of real lives.
- Three major hospital systems and a government health institute are coordinating the effort, signaling institutional confidence that wearable, cuffless technology has crossed from novelty into clinical legitimacy.
- The study's data could expose patterns — like blood pressure that appears normal in clinics but surges at home — that current treatment guidelines may not yet adequately address for aging, rural populations.
- For the broader field, success here would build the evidentiary case for replacing occasional clinical readings with a richer, more personal map of each patient's cardiovascular landscape.
Sky Labs announced this week that its CART BP Pro — a ring worn on the finger rather than a cuff on the arm — will serve as the primary monitoring tool in a government-led cardiovascular study of approximately 770 adults aged 65 and older living in rural South Korea. The study operates under KoGES, the Korean Genome and Epidemiology Study, overseen by the Korea National Institute of Health within the Korea Disease Control and Prevention Agency, with cardiologists and epidemiologists from Hanyang University Hospital, Keimyung University Dongsan Hospital, and Severance Hospital contributing to the research team.
What distinguishes this deployment is its setting. Rather than capturing readings in the controlled quiet of a clinic, the ring will collect continuous blood pressure data as participants move through their daily routines and sleep — the kind of unfiltered, real-world monitoring that traditional cuff-based devices cannot provide. The CART BP Pro earned reimbursement coverage for 24-hour ambulatory monitoring in 2024 and was subsequently included in the Korean Society of Hypertension's 2026 treatment guidelines, marking its transition from emerging technology to clinically recognized tool.
The scientific motivation runs deeper than convenience. Blood pressure fluctuates constantly — with activity, emotion, time of day, and sleep — and those fluctuations carry meaningful cardiovascular information that a single office reading cannot capture. Phenomena like white-coat hypertension, where pressure appears normal in clinical settings but rises at home, are well documented but difficult to study at scale. By tracking hundreds of older adults continuously over time, researchers hope to map individual variation and identify which patterns genuinely predict cardiovascular risk.
The focus on rural older adults is deliberate. Aging bodies face higher rates of hypertension, yet rural communities often lack consistent access to medical monitoring. Insights drawn from this population could reveal whether existing treatment guidelines adequately serve people living outside major urban centers — and may ultimately push clinical practice toward a more granular, continuous understanding of each patient's blood pressure life. Sky Labs offered no timeline for completion, but the scale of institutional involvement suggests a multi-year commitment with implications that could extend well beyond Korea's borders.
A South Korean medical device company announced this week that its wearable blood pressure monitor will anchor a major government study tracking cardiovascular health in older adults. Sky Labs' CART BP Pro—a ring worn on the finger rather than a cuff wrapped around the arm—has been selected to collect continuous blood pressure readings from roughly 770 people aged 65 and older living in rural communities across the country.
The study operates under KoGES, the Korean Genome and Epidemiology Study, a long-running national research initiative overseen by the Korea National Institute of Health, which sits within the Korea Disease Control and Prevention Agency. The research team includes cardiologists and epidemiologists from three major hospital systems: Hanyang University Hospital, Keimyung University Dongsan Hospital, and Severance Hospital. What makes this deployment significant is not just the scale, but the setting—researchers will be monitoring blood pressure in real-world conditions, capturing readings while participants go about their daily routines and while they sleep, rather than in the controlled environment of a clinic.
The CART BP Pro itself represents a shift in how blood pressure monitoring happens. Unlike traditional cuff-based devices that require a person to sit still for a reading, the ring collects data continuously throughout the day and night. The device gained traction in Korea's healthcare system after receiving reimbursement coverage for 24-hour ambulatory blood pressure monitoring in 2024—a regulatory milestone that essentially certified its accuracy and clinical utility. The Korean Society of Hypertension further validated the technology by including it in its 2026 treatment guidelines, signaling that major medical institutions now consider it a legitimate tool for managing high blood pressure.
For researchers, the appeal is straightforward: blood pressure is not static. It fluctuates with activity, stress, sleep, and time of day. Understanding these variations—and how they differ from person to person—has long been difficult to study at scale. A person might have normal readings in a doctor's office but elevated pressure at home, a phenomenon so common it has its own name: white-coat hypertension. Conversely, some people show the opposite pattern. By collecting continuous data from hundreds of older adults over time, the study aims to map these individual variations and identify which patterns correlate with actual cardiovascular risk.
Why focus on older adults in rural areas? Aging populations face higher rates of hypertension and cardiovascular disease, yet rural communities often have less access to consistent medical monitoring. A study that captures real-world blood pressure patterns in this population could reveal insights specific to how aging bodies manage blood pressure regulation, and whether current treatment guidelines adequately address the needs of people living outside major urban centers. The data collected could ultimately reshape how doctors approach hypertension management in older patients—moving from occasional clinic readings to a more granular understanding of each person's actual blood pressure landscape.
Sky Labs framed the study as an opportunity to advance understanding of blood pressure variability and cardiovascular risk factors in aging populations. The company did not announce a timeline for the study's completion or when results might be published, but the involvement of major academic hospitals and a government health institute suggests this is a multi-year commitment. For the device maker, the study represents both validation and opportunity: successful data collection could strengthen the case for wider adoption of cuffless monitoring technology in Korea and potentially beyond.
Citas Notables
Data collected through the study could help researchers better understand blood pressure variability and cardiovascular risk factors among older adults.— Sky Labs
La Conversación del Hearth Otra perspectiva de la historia
Why does it matter that this study is happening in rural areas specifically?
Rural older adults often have less frequent contact with healthcare providers. A continuous monitoring device captures what's actually happening to their blood pressure over weeks and months, not just the snapshot you get during a clinic visit. That real-world data is what's missing from most hypertension research.
So the ring is just collecting data—it's not treating anything?
Exactly. It's a measurement tool. But better measurement changes treatment. If you can see that someone's blood pressure spikes at night, or dips dangerously during certain activities, you can adjust their medication or lifestyle in ways that wouldn't make sense based on office readings alone.
The device got reimbursement coverage in 2024. Does that mean insurance will pay for it?
In Korea, yes—at least for the specific use of 24-hour ambulatory monitoring. That's significant because it removes a financial barrier. People can actually use it without paying out of pocket, which matters for a study recruiting older adults who may be on fixed incomes.
What happens to the data after the study ends?
That's not spelled out in what we know so far. But given that this is a government-led epidemiology study, the data will likely be analyzed to inform national health policy and treatment guidelines. The Korean Society of Hypertension already cited this kind of research when they updated their guidelines in 2026.
Is this a competitive advantage for Sky Labs?
It's both validation and a moat. If the study produces strong data showing the device works well in real-world conditions, it becomes harder for competitors to argue their devices are better. And the company gets to say their technology helped shape national health policy.